Wróć

Wybierz swój region

Corporate

Europa:

Flaga Albania Albania Flaga Bośnia i Hercegowina Bośnia i Hercegowina Flaga Bułgaria Bułgaria Flaga Chorwacja Chorwacja Flaga Cypr Cypr Flaga Czarnogóra Czarnogóra Flaga Czechy Czechy Flaga Dania Dania Flaga Estonia Estonia Flaga Hiszpania Hiszpania Flaga Kosowo Kosowo Flaga Litwa Litwa Flaga Łotwa Łotwa Flaga Luksemburg Luksemburg Flaga Macedonia Macedonia Flaga Niemcy Niemcy Flaga Polska Polska Flaga Portugalia Portugalia Flaga Rumunia Rumunia Flaga Serbia Serbia Flaga Słowacja Słowacja Flaga Słowenia Słowenia Flaga Szwajcaria Szwajcaria Flaga Szwecja Szwecja Flaga Turcja Turcja Flaga Węgry Węgry Flaga Wielka Brytania Wielka Brytania Flaga Włochy Włochy

Azja:

Flaga UAE UAE Flaga Hong Kong Hong Kong Flaga Kuwejt Kuwejt Flaga Liban Liban

Afryka:

Flaga RPA RPA

Umów konsultację o krwi pępowinowej

Umawiam

Skontaktuj się z nami już dziś!

Chcesz dowiedzieć się więcej o naszych usługach? Uzupełnij poniższy formularz, a my skontaktujemy się z Tobą jak najszybciej, aby udzielić Ci wszelkich potrzebnych informacji oraz odpowiedzieć na Twoje pytania.

    Uprzejmie informujemy, że dane osobowe podane w formularzu będą przetwarzane przez Polski Bank Komórek Macierzystych Sp. z o.o. („PBKM”) z siedzibą w Warszawie, Al. Jana Pawła II 29 w celu kontaktu telefonicznego w związku z udzieleniem informacji na temat usługi.

    Zestawienie leczonych pacjentów

    Terapie
    komórkami macierzystymi

    Terapie komórkami macierzystymi

    Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).

    Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.

    Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.

    Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.

    Data aktualizacji: 06.2026

    Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord

    Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
    Lp. Źródło Typ źródła Wskazanie Obszar medycyny Rok podania Terapia Kraj Wiek odbiorcy
    6501 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2018 Standard Therapy Poland 54
    6502 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2018 Standard Therapy Germany 72
    6503 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2018 Standard Therapy Germany 54
    6504 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2018 Standard Therapy Germany 58
    6505 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2018 Standard Therapy Germany 63
    6506 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2018 Standard Therapy Germany 48
    6507 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2018 Standard Therapy Germany 62
    6508 Apheresis Allogeneic Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma Hematology 2018 Standard Therapy Poland 62
    6509 Apheresis Autologous Non-Hodgkin-Lymphoma-Relapse Hematology 2018 Standard Therapy Germany 51
    6510 Apheresis Allogeneic Other Malignancy Hematology 2018 Standard Therapy Poland 59
    6511 Apheresis Allogeneic Other Myelodysplastic Syndromes Hematology 2018 Standard Therapy Poland 67
    6512 Apheresis Allogeneic Other Myelofibrosis Hematology 2018 Standard Therapy Poland 57
    6513 Apheresis Allogeneic Peripheral T-Cell Lymphoma Hematology 2018 Standard Therapy Poland 50
    6514 Apheresis Allogeneic Plasma Cell Disorder Hematology 2018 Standard Therapy Poland 64
    6515 Apheresis Allogeneic Plasma Cell Disorder Hematology 2018 Standard Therapy Poland 57
    6516 Apheresis Autologous Plasma Cell Leukemia Hematology 2018 Standard Therapy Germany 52
    6517 Apheresis Allogeneic Post-Essential Thrombocythemia-Myelofibrosis Hematology 2018 Standard Therapy Germany 53
    6518 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2018 Standard Therapy Germany 67
    6519 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2018 Standard Therapy Germany 69
    6520 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2018 Standard Therapy Germany 66
    6521 Apheresis Autologous Primary Central Nervous System Lymphoma Relapse Hematology 2018 Standard Therapy Germany 63
    6522 Apheresis Allogeneic Primary Immunodeficiency Hematology 2018 Standard Therapy Poland 3
    6523 Apheresis Allogeneic Primary Myelofibrosis; Secondary Acute Myelogenous Leukemia Hematology 2018 Standard Therapy Poland 53
    6524 Apheresis Allogeneic Prolymphocytic Leukemia Hematology 2018 Standard Therapy Poland 62
    6525 Apheresis Autologous Refractory Diffuse Large B-Cell Lymphoma Hematology 2018 Standard Therapy Germany 36
    6526 Apheresis Allogeneic Refractory Diffuse Large B-Cell Lymphoma Hematology 2018 Standard Therapy Germany 50
    6527 Apheresis Allogeneic Secondary Acute Myeloid Leukemia Hematology 2018 Standard Therapy Poland 58
    6528 Apheresis Allogeneic Secondary Acute Myeloid Leukemia Hematology 2018 Standard Therapy Germany 68
    6529 Apheresis Allogeneic Secondary Acute Myeloid Leukemia At Primary Myelofibrosis Hematology 2018 Standard Therapy Germany 56
    6530 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2018 Standard Therapy Poland 18
    6531 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2018 Standard Therapy Poland 74
    6532 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2018 Standard Therapy Poland 24
    6533 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2018 Standard Therapy Poland 70
    6534 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2018 Standard Therapy Poland 6
    6535 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2018 Standard Therapy Poland 13
    6536 Apheresis Allogeneic Severe Combined Immunodeficiency Hematology 2018 Standard Therapy Poland 2
    6537 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2018 Standard Therapy Poland 7
    6538 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2018 Standard Therapy Poland 13
    6539 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2018 Standard Therapy Poland 45
    6540 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2018 Standard Therapy Poland 40
    6541 Apheresis Autologous T-Cell Non-Hodgkin Lymphoma Hematology 2018 Standard Therapy Germany 67
    6542 Apheresis Autologous T-Cell-Lymphoma Hematology 2018 Standard Therapy Germany 67
    6543 Apheresis Allogeneic T-Cell-Lymphoma Hematology 2018 Standard Therapy Germany 23
    6544 Apheresis Allogeneic Thalassemia Major Hematology 2018 Standard Therapy Poland 5
    6545 Apheresis Allogeneic Therapy-Related Myelodysplastic Syndromes Hematology 2018 Standard Therapy Poland 65
    6546 Adipose Tissue Autologous Condition After Injury Of The Left Knee Joint Orthopedy 2018 Experimental Therapy Poland 33
    6547 Adipose Tissue Autologous Coxarthrosis Orthopedy 2018 Experimental Therapy Poland 53
    6548 Adipose Tissue Autologous Cutis Laxa Dermatology 2018 Clinical Trial Poland 0
    6549 Adipose Tissue Autologous Cutis Laxa Dermatology 2018 Clinical Trial Poland 0
    6550 Adipose Tissue Autologous Cutis Laxa Dermatology 2018 Clinical Trial Poland 0
    6551 Adipose Tissue Autologous Cutis Laxa Dermatology 2018 Clinical Trial Poland 0
    6552 Adipose Tissue Autologous Cutis Laxa Dermatology 2018 Clinical Trial Poland 0
    6553 Adipose Tissue Autologous Cutis Laxa Dermatology 2018 Clinical Trial Poland 0
    6554 Adipose Tissue Autologous Cutis Laxa Dermatology 2018 Clinical Trial Poland 0
    6555 Adipose Tissue Autologous Cutis Laxa Dermatology 2018 Clinical Trial Poland 0
    6556 Adipose Tissue Autologous Gonarthrosis Orthopedy 2018 Experimental Therapy Poland 69
    6557 Adipose Tissue Autologous Gonarthrosis Orthopedy 2018 Experimental Therapy Poland 42
    6558 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6559 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6560 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6561 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6562 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6563 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6564 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6565 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6566 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6567 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6568 Adipose Tissue Autologous Scar Dermatology 2018 Clinical Trial Poland 0
    6569 Cord Tissue Allogeneic – Unrelated Limb-Girdle Muscular Dystrophy Neurology 2017 Experimental Therapy Poland 44
    6570 Cord Tissue Allogeneic – Unrelated Limb-Girdle Muscular Dystrophy Neurology 2017 Experimental Therapy Poland 25
    6571 Cord Tissue Allogeneic – Unrelated Limb-Girdle Muscular Dystrophy Neurology 2017 Experimental Therapy Poland 38
    6572 Cord Tissue Allogeneic – Unrelated Limb-Girdle Muscular Dystrophy Neurology 2017 Experimental Therapy Poland 26
    6573 Cord Tissue Allogeneic – Unrelated Limb-Girdle Muscular Dystrophy Neurology 2017 Experimental Therapy Poland 37
    6574 Cord Tissue Allogeneic – Unrelated Limb-Girdle Muscular Dystrophy Neurology 2017 Experimental Therapy Poland 62
    6575 Cord Tissue Allogeneic – Unrelated Limb-Girdle Muscular Dystrophy Neurology 2017 Experimental Therapy Poland 35
    6576 Cord Tissue Allogeneic – Unrelated Limb-Girdle Muscular Dystrophy Neurology 2017 Experimental Therapy Poland 31
    6577 Cord Tissue Allogeneic – Unrelated Acute Graft Versus Host Disease Hematology 2017 Experimental Therapy Poland 13
    6578 Cord Tissue Allogeneic – Unrelated Acute Graft Versus Host Disease Hematology 2017 Experimental Therapy Poland 11
    6579 Cord Tissue Allogeneic – Unrelated Acute Graft Versus Host Disease Hematology 2017 Experimental Therapy Poland 2
    6580 Cord Tissue Allogeneic – Unrelated Acute Graft Versus Host Disease Hematology 2017 Experimental Therapy Poland 8
    6581 Cord Tissue Allogeneic – Unrelated Acute Graft Versus Host Disease Hematology 2017 Experimental Therapy Poland 7
    6582 Cord Tissue Allogeneic – Unrelated Age-Related Macular Degeneration Ophthalmology 2017 Experimental Therapy Poland 33
    6583 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 67
    6584 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 37
    6585 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 71
    6586 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 0
    6587 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 47
    6588 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 56
    6589 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 48
    6590 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 46
    6591 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 45
    6592 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 75
    6593 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 51
    6594 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 59
    6595 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 64
    6596 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 56
    6597 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 40
    6598 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 69
    6599 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 52
    6600 Cord Tissue Allogeneic – Unrelated Amyotrophic Lateral Sclerosis Neurology 2017 Experimental Therapy Poland 35